---
layout: default
title: Flavoxate
parent: 僅模型預測 (L5)
nav_order: 429
evidence_level: L5
indication_count: 10
---

# Flavoxate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Flavoxate: From Overactive Bladder to Attention Deficit Hyperactivity Disorder (Inattentive Type)

## One-Sentence Summary

Flavoxate is a urinary antispasmodic drug historically used to manage overactive bladder symptoms (urinary urgency, frequency, and dysuria) through smooth muscle relaxation and weak anticholinergic activity.
The TxGNN model predicts it may be effective for **Attention Deficit Hyperactivity Disorder, Inattentive Type**,
however **no clinical trials or published literature** currently support this direction, and the mechanistic rationale is counter-directional — anticholinergic agents impair rather than improve attention.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Overactive bladder / urinary antispasmodic (urinary urgency, frequency, dysuria) — based on pharmacological class; no Singapore registration on record |
| Predicted New Indication | Attention Deficit Hyperactivity Disorder, Inattentive Type |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on the pharmacological context embedded in the prediction rationale, Flavoxate is a urinary antispasmodic that relaxes detrusor smooth muscle primarily through phosphodiesterase (PDE) inhibition — raising intracellular cAMP — with secondary weak anticholinergic (muscarinic antagonist) properties. Its established clinical niche is overactive bladder: urinary frequency, urgency, nocturia, and dysuria. Tissue distribution data suggests preferential accumulation in urological tissues, with limited central nervous system penetration.

The predicted new indication — ADHD inattentive type — involves dysregulation of dopaminergic and noradrenergic neurotransmission in prefrontal cortical circuits. First-line ADHD pharmacotherapy (methylphenidate, amphetamines, atomoxetine, guanfacine) targets these pathways specifically. Flavoxate's weak anticholinergic action runs in the **opposite direction**: reducing acetylcholine signalling generally impairs sustained attention and working memory, as evidenced by the well-documented cognitive side-effect profiles of anticholinergic drugs. Additionally, Flavoxate's PDE inhibitory activity lacks selectivity for the CNS-relevant PDE4 and PDE10 subtypes implicated in ADHD neuropharmacology.

The high TxGNN prediction score for both ADHD node variants (ranks 1 and 4 in this pack) almost certainly reflects knowledge graph proximity between neurological/developmental condition nodes rather than a true pharmacological signal. Among all 10 predicted indications, **neurogenic bladder (rank 6, score 99.13%)** represents the most mechanistically coherent repurposing candidate — Flavoxate's core mechanism of detrusor relaxation directly addresses detrusor overactivity in neurogenic bladder, and this aligns with its historical use for overactive bladder symptoms. Clinicians and reviewers should treat neurogenic bladder as the primary candidate for any further investigation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Flavoxate in ADHD inattentive type.

---

## Literature Evidence

Currently no related literature available for Flavoxate in ADHD inattentive type.

---

## Singapore Market Information

Flavoxate is currently **not registered** in Singapore. No product licenses or approved indications are on record as of the data cutoff (2026-06-21).

---

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction data was identified in this evidence search. Full TFDA/HSA labelling warnings and contraindications have not been retrieved and represent a blocking data gap before clinical evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN model score (99.75%), there is zero supporting clinical or published literature evidence for Flavoxate in ADHD inattentive type, and the drug's anticholinergic mechanism is pharmacologically counter-directional to established ADHD treatment targets — making this prediction biologically implausible as a repurposing lead.

**To proceed with any evaluation, the following is needed:**

- **Redirect the primary repurposing focus** to neurogenic bladder (rank 6), which aligns directly with Flavoxate's established PDE-inhibitory mechanism and has a coherent pharmacological rationale
- **Retrieve full MOA data** from DrugBank or primary literature to confirm CNS penetration profile before any neurological indication is considered
- **Obtain Singapore/TFDA package insert** to resolve the blocking safety data gap (DG001: warnings and contraindications)
- **Literature review of Flavoxate in OAB and neurogenic bladder** to establish a clinical evidence baseline before branching to adjacent indications
- **Preclinical CNS data** (BBB penetration, receptor binding affinity at CNS targets) would be required before ADHD or any CNS indication could progress beyond a research question

> ⚠️ *This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

